AU773891C - Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity - Google Patents

Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity

Info

Publication number
AU773891C
AU773891C AU12239/00A AU1223900A AU773891C AU 773891 C AU773891 C AU 773891C AU 12239/00 A AU12239/00 A AU 12239/00A AU 1223900 A AU1223900 A AU 1223900A AU 773891 C AU773891 C AU 773891C
Authority
AU
Australia
Prior art keywords
seq
iegptlrqwlaara
group
gly
tmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired, expires
Application number
AU12239/00A
Other languages
English (en)
Other versions
AU1223900A (en
AU773891B2 (en
Inventor
Janet Cheetham
Ulrich Feige
Chuan-Fa Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AU1223900A publication Critical patent/AU1223900A/en
Publication of AU773891B2 publication Critical patent/AU773891B2/en
Application granted granted Critical
Publication of AU773891C publication Critical patent/AU773891C/en
Assigned to KIRIN-AMGEN INC. reassignment KIRIN-AMGEN INC. Alteration of Name(s) in Register under S187 Assignors: AMGEN, INC.
Adjusted expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU12239/00A 1998-10-23 1999-10-22 Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity Expired AU773891C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10534898P 1998-10-23 1998-10-23
US60/105348 1998-10-23
PCT/US1999/024834 WO2000024770A2 (en) 1998-10-23 1999-10-22 Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity

Publications (3)

Publication Number Publication Date
AU1223900A AU1223900A (en) 2000-05-15
AU773891B2 AU773891B2 (en) 2004-06-10
AU773891C true AU773891C (en) 2005-02-17

Family

ID=22305310

Family Applications (1)

Application Number Title Priority Date Filing Date
AU12239/00A Expired AU773891C (en) 1998-10-23 1999-10-22 Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity

Country Status (36)

Country Link
US (8) US6835809B1 (OSRAM)
EP (3) EP1124961B9 (OSRAM)
JP (2) JP3820105B2 (OSRAM)
KR (1) KR100719202B1 (OSRAM)
CN (2) CN1810832B (OSRAM)
AR (1) AR020934A1 (OSRAM)
AT (1) ATE348163T1 (OSRAM)
AU (1) AU773891C (OSRAM)
BG (3) BG65663B1 (OSRAM)
BR (1) BRPI9914698B8 (OSRAM)
CA (1) CA2346996C (OSRAM)
CY (4) CY1107526T1 (OSRAM)
CZ (1) CZ302155B6 (OSRAM)
DE (2) DE122009000039I1 (OSRAM)
DK (3) DK1124961T3 (OSRAM)
EA (1) EA003998B1 (OSRAM)
ES (3) ES2422231T3 (OSRAM)
FR (1) FR09C0030I2 (OSRAM)
HK (1) HK1042114B (OSRAM)
HU (1) HU228582B1 (OSRAM)
IL (1) IL142023A0 (OSRAM)
LT (1) LTC1124961I2 (OSRAM)
LU (1) LU91598I2 (OSRAM)
ME (2) MEP42108A (OSRAM)
MY (1) MY126795A (OSRAM)
NL (1) NL300398I2 (OSRAM)
NO (2) NO331027B1 (OSRAM)
NZ (1) NZ510529A (OSRAM)
PL (1) PL219605B1 (OSRAM)
PT (3) PT1783222E (OSRAM)
RS (1) RS51237B (OSRAM)
SI (3) SI1783222T1 (OSRAM)
SK (1) SK287737B6 (OSRAM)
TW (2) TWI250988B (OSRAM)
WO (1) WO2000024770A2 (OSRAM)
ZA (1) ZA200102102B (OSRAM)

Families Citing this family (158)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
PL219605B1 (pl) 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA02010351A (es) * 2000-04-21 2003-04-25 Amgen Inc Antagonistas de integrina/adhesion.
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
ATE275979T1 (de) * 2000-06-09 2004-10-15 Us Gov Health & Human Serv Pegylation von linker verbessert die antitumor- aktivität und verringert die toxizität von immunkonjugaten
EP1589034B1 (en) * 2000-12-05 2008-11-19 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040018203A1 (en) * 2001-06-08 2004-01-29 Ira Pastan Pegylation of linkers improves antitumor activity and reduces toxicity of immunoconjugates
EP1434798B1 (en) 2001-08-17 2012-04-04 Enkam Pharmaceuticals A/S Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival of cells
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
EP1542714B1 (en) * 2002-09-18 2014-04-02 Ortho-McNeil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
CA2525497A1 (en) 2003-05-12 2004-11-25 Affymax, Inc. Peptides that bind to the erythropoietin receptor
KR20060028675A (ko) * 2003-05-12 2006-03-31 아피맥스, 인크. 신규한 폴리 (에틸렌 글리콜) 개질 화합물 및 그의 용도
AU2004238870B8 (en) 2003-05-12 2010-04-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
BRPI0411166A (pt) 2003-05-12 2006-07-18 Affymax Inc composto compreendendo uma parcela de peptìdeo, uma parcela espaçadora e uma parcela de polìmero solúvel em água e composição farmacêutica compreendendo tal composto
EP1765411B2 (en) * 2004-06-30 2017-10-11 Nektar Therapeutics Polymer-factor ix moiety conjugates
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
DK1797127T3 (en) 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
WO2006136450A2 (en) * 2005-06-23 2006-12-28 Aplagen Gmbh Supravalent compounds
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007075899A2 (en) * 2005-12-21 2007-07-05 Maxygen, Inc. Dual agonist compounds and uses thereof
WO2007102946A2 (en) * 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
AU2007278748B2 (en) 2006-07-24 2013-08-15 The University Of Queensland Method of producing a population of cells
CA2676820A1 (en) 2007-01-31 2008-08-07 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
US20110097318A1 (en) * 2007-08-31 2011-04-28 Amgen Inc. Solid-State Protein Formulation
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
WO2009068042A2 (en) 2007-11-28 2009-06-04 Enkam Pharmaceuticals A/S Novel peptides derived from ncam (fgls)
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
SG175004A1 (en) 2009-04-02 2011-11-28 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
NZ701769A (en) 2009-09-16 2016-06-24 Genentech Inc Coiled coil and/or tether containing protein complexes and uses thereof
US20120253009A1 (en) * 2009-10-16 2012-10-04 Amgen Inc. Thrombopoietic compounds
US9662271B2 (en) 2009-10-23 2017-05-30 Amgen Inc. Vial adapter and system
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
CN102946906B (zh) 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
JP5981423B2 (ja) 2010-06-07 2016-08-31 アムジエン・インコーポレーテツド 薬物送達デバイス
BR112013003279A2 (pt) 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
WO2012040518A2 (en) 2010-09-22 2012-03-29 Amgen Inc. Carrier immunoglobulins and uses thereof
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2825064C (en) 2011-02-04 2022-08-30 Genentech, Inc. Fc variants and methods for their production
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
PL2699293T3 (pl) 2011-04-20 2019-08-30 Amgen Inc. Urządzenie do wstrzykiwania automatycznego
RU2654567C2 (ru) 2011-10-11 2018-05-21 Дженентек, Инк. Улучшенная сборка биспецифических антител
ES2675035T3 (es) 2011-10-14 2018-07-05 Amgen, Inc Inyector y método de ensamblaje
RU2644341C2 (ru) 2012-02-10 2018-02-08 Дженентек, Инк. Одноцепочечные антитела и другие гетеромультимеры
CN102552184A (zh) * 2012-02-16 2012-07-11 山东泉港药业有限公司 一种血小板生成素拟肽冻干制剂
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
EP2867254B1 (en) 2012-06-27 2017-10-25 F. Hoffmann-La Roche AG Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
SI3081249T1 (sl) 2012-11-21 2021-03-31 Amgen Inc. Naprava za dajanje zdravila
JP6643977B2 (ja) 2013-03-15 2020-02-12 アムゲン・インコーポレーテッド 体輪郭に適応可能な自動注入機デバイス
CN104046642B (zh) * 2013-03-15 2018-07-06 兰州大学 发酵生产二聚体化融合蛋白的方法
EP2968775B1 (en) 2013-03-15 2019-12-18 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
CN104045715B (zh) * 2013-03-15 2018-05-01 兰州大学 二聚体化融合蛋白的制备及应用
EP2968760B1 (en) 2013-03-15 2024-01-03 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
MX378820B (es) 2013-03-22 2025-03-10 Amgen Inc Inyector y método de montaje.
BR112015027288B1 (pt) 2013-05-03 2022-03-15 Selecta Biosciences, Inc Composição que compreende um inibidor de mtor ligado a nanocarreadores sintéticos poliméricos
EP3501575B1 (en) 2013-10-24 2021-12-01 Amgen Inc. Drug delivery system with temperature-sensitive-control
ES3010716T3 (en) 2013-10-24 2025-04-04 Amgen Inc Injector and method of assembly
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
CN105017408B (zh) * 2014-04-30 2019-11-05 重庆派金生物科技有限公司 聚乙二醇化血小板生成素模拟肽同源四聚体及其用途
PL3140392T3 (pl) 2014-05-06 2023-11-27 F. Hoffmann-La Roche Ag Produkcja białek heteromultimerycznych z wykorzystaniem komórek ssaków
EP3139977B1 (en) 2014-05-07 2021-02-17 Amgen Inc. Autoinjector with shock reducing elements
SG11201609966SA (en) 2014-06-03 2016-12-29 Amgen Inc Drug delivery system and method of use
US10112977B2 (en) 2014-06-23 2018-10-30 Toagosei Co., Ltd. Peptide for inducing multinucleation in cells, and use therefor
KR20170062490A (ko) * 2014-09-26 2017-06-07 바이엘 파마 악티엔게젤샤프트 안정화된 아드레노메둘린 유도체 및 그의 용도
WO2016061220A2 (en) 2014-10-14 2016-04-21 Amgen Inc. Drug injection device with visual and audio indicators
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
EP3848072A1 (en) 2014-12-19 2021-07-14 Amgen Inc. Drug delivery device with proximity sensor
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
WO2016129656A1 (ja) * 2015-02-12 2016-08-18 国立大学法人岩手大学 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤
WO2016133947A1 (en) 2015-02-17 2016-08-25 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
JP2018512184A (ja) 2015-02-27 2018-05-17 アムジエン・インコーポレーテツド 針ガードの移動に対する抵抗力の閾値が調整可能な針ガード機構を備えた薬物送達装置
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
ES3039908T3 (en) 2016-03-15 2025-10-27 Amgen Inc Reducing probability of glass breakage in drug delivery devices
US11541168B2 (en) 2016-04-29 2023-01-03 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
US11238150B2 (en) 2016-05-16 2022-02-01 Amgen Inc. Data encryption in medical devices with limited computational capability
US11541176B2 (en) 2016-06-03 2023-01-03 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US11285266B2 (en) 2016-07-01 2022-03-29 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
EP3532127A1 (en) 2016-10-25 2019-09-04 Amgen Inc. On-body injector
CN108264547B (zh) * 2016-12-30 2021-09-21 四川科伦博泰生物医药股份有限公司 一种纯化蛋白的方法以及试剂盒
AU2018210301A1 (en) 2017-01-17 2019-08-01 Amgen Inc. Injection devices and related methods of use and assembly
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
EP3582829A1 (en) 2017-02-17 2019-12-25 Amgen Inc. Insertion mechanism for drug delivery device
ES3051784T3 (en) 2017-03-06 2025-12-30 Amgen Inc Drug delivery device with activation prevention feature
US11571511B2 (en) 2017-03-07 2023-02-07 Amgen Inc. Insertion mechanism and method of inserting a needle of a drug delivery device
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
CA3055936A1 (en) 2017-03-11 2018-09-20 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
LT3600491T (lt) 2017-03-28 2023-10-10 Amgen Inc. Stūmoklio koto ir švirkšto konstrukcinė sistema ir būdas
US11590294B2 (en) 2017-06-08 2023-02-28 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
JP7195276B2 (ja) 2017-06-22 2022-12-23 アムジエン・インコーポレーテツド デバイス起動による衝突／衝撃の低減
JP7475860B2 (ja) 2017-06-23 2024-04-30 アムジエン・インコーポレーテツド スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. NEEDLE INSERTION-RETRACTING SYSTEM HAVING DOUBLE TORSION SPRING SYSTEM
EP3655063A1 (en) 2017-07-21 2020-05-27 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
WO2019022950A1 (en) 2017-07-25 2019-01-31 Amgen Inc. DRUG DELIVERY DEVICE WITH CONTAINER ACCESS SYSTEM AND ASSEMBLY METHOD THEREOF
US11617837B2 (en) 2017-07-25 2023-04-04 Amgen Inc. Drug delivery device with gear module and related method of assembly
EP3664863A2 (en) 2017-08-09 2020-06-17 Amgen Inc. Hydraulic-pneumatic pressurized chamber drug delivery system
MA49897A (fr) 2017-08-18 2020-06-24 Amgen Inc Injecteur sur-corps avec patch adhésif stérile
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
US11759565B2 (en) 2017-10-04 2023-09-19 Amgen Inc. Flow adapter for drug delivery device
EP4257164A3 (en) 2017-10-06 2024-01-17 Amgen Inc. Drug delivery device with interlock assembly and related method of assembly
EP3694578B1 (en) 2017-10-09 2025-09-24 Amgen Inc. Drug delivery device with drive assembly and related method of assembly
EP3703778A1 (en) 2017-11-03 2020-09-09 Amgen Inc. System and approaches for sterilizing a drug delivery device
MA50569A (fr) 2017-11-06 2020-09-16 Amgen Inc Ensembles de remplissage-finition et procédés associés
MA50553A (fr) 2017-11-06 2020-09-16 Amgen Inc Dispositif d'administration de médicament avec détection de positionnement et de débit
EP3706826A1 (en) 2017-11-10 2020-09-16 Amgen Inc. Plungers for drug delivery devices
SG11202002772VA (en) 2017-11-16 2020-04-29 Amgen Inc Autoinjector with stall and end point detection
AU2018368340B2 (en) 2017-11-16 2024-03-07 Amgen Inc. Door latch mechanism for drug delivery device
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
EP3586860A1 (en) * 2018-06-22 2020-01-01 Universität Ulm Complement inhibitors and uses thereof
CA3103682A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Delivery devices for administering drugs
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
WO2020023336A1 (en) 2018-07-24 2020-01-30 Amgen Inc. Hybrid drug delivery devices with grip portion
EP3826701A1 (en) 2018-07-24 2021-06-02 Amgen Inc. Delivery devices for administering drugs
WO2020028009A1 (en) 2018-07-31 2020-02-06 Amgen Inc. Fluid path assembly for a drug delivery device
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
MA53718A (fr) 2018-09-28 2022-01-05 Amgen Inc Ensemble d'activation d'échappement de fil de muscle pour un dispositif d'administration de médicament
MX2021003492A (es) 2018-10-02 2021-06-18 Amgen Inc Sistemas de inyeccion para la administracion de farmacos con transmision de fuerza interna.
TW202529830A (zh) 2018-10-05 2025-08-01 美商安進公司 具有劑量指示器之藥物遞送裝置
SG11202101824VA (en) 2018-10-15 2021-03-30 Amgen Inc Platform assembly process for drug delivery device
KR20250127186A (ko) 2018-10-15 2025-08-26 암젠 인크 댐핑 메커니즘을 갖는 약물 전달 장치
SG11202104199WA (en) * 2018-10-26 2021-05-28 Kyowa Kirin Co Ltd Pharmaceutical composition for treating aplastic anemia
WO2020091956A1 (en) 2018-11-01 2020-05-07 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
WO2020219482A1 (en) 2019-04-24 2020-10-29 Amgen Inc. Syringe sterilization verification assemblies and methods
WO2020223303A1 (en) 2019-04-29 2020-11-05 The Children's Hospital Of Philadelphia Compositions and methods for increasing megakaryocyte production
MX2022002149A (es) 2019-08-23 2022-03-17 Amgen Inc Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
WO2022129460A1 (en) 2020-12-18 2022-06-23 Richter Gedeon Nyrt. Methods for the purification of refolded fc-peptide fusion protein
WO2022182920A1 (en) * 2021-02-24 2022-09-01 Purdue Research Foundation Osteotropic compositions and uses thereof
CN113402614A (zh) * 2021-04-22 2021-09-17 山东泉港药业有限公司 血小板生成素拟肽融合蛋白(fc-tmp)编码基因与应用
WO2022246055A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
WO2023044774A1 (en) * 2021-09-24 2023-03-30 Sichuan Clover Biopharmaceuticals, Inc. Tpo mimetic fusion proteins and methods of use submission of sequence listing as ascii text file
WO2023149443A1 (ja) 2022-02-02 2023-08-10 国立大学法人 筑波大学 臍帯血移植後の血球回復のための医薬組成物
MX2024010846A (es) 2022-03-24 2024-09-11 Richter Gedeon Nyrt Metodo para la preparacion de biofarmacos.
CA3264659A1 (en) 2022-08-11 2024-02-15 Cartesian Therapeutics, Inc. COMPOSITIONS AND PROCESSES ASSOCIATED WITH IMMUNOGLOBULIN PROTEASES AND FUSION THEREOF
WO2025037108A2 (en) 2023-08-15 2025-02-20 Board Of Trustees Of The Leland Stanford Junior University Modified thrombopoietin
CN117986346B (zh) * 2024-04-07 2024-07-26 中国人民解放军军事科学院军事医学研究院 一种tpo模拟肽及其应用
CN119780301B (zh) * 2025-01-10 2025-08-01 山东泉港药业有限公司 一种血小板生成素拟肽的肽图检测分析方法

Family Cites Families (178)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2043149A1 (de) * 1969-09-01 1971-11-04 Geetainers (Europe) Ltd., St. Aubin, Jersey, Channel Isles (Großbritannien) Deckelverschluß für Transportbehälter
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4002531A (en) * 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4503235A (en) 1983-03-11 1985-03-05 Warner-Lambert Company Process for producing 4-carbamoyl-1H-imidazolium-5-olate
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5985599A (en) * 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
EP0315456B1 (en) 1987-11-05 1994-06-01 Hybritech Incorporated Polysaccharide-modified immunoglobulins having reduced immunogenic potential or improved pharmacokinetics
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
ES2092468T3 (es) 1988-01-22 1996-12-01 Zymogenetics Inc Metodos para producir analogos de receptores secretados.
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8824591D0 (en) 1988-10-20 1988-11-23 Royal Free Hosp School Med Fractionation process
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
AU638964B2 (en) * 1988-12-22 1993-07-15 Genentech Inc. Method for preparing water soluble polypeptides
US5089261A (en) * 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5098833A (en) * 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5216131A (en) * 1989-02-23 1993-06-01 Genentech, Inc. Lymphocyte homing receptors
US5627262A (en) * 1989-07-05 1997-05-06 The Board Of Regents Of The University Of Oklahoma Method and composition for the treatment of septic shock
ATE236249T1 (de) * 1989-09-12 2003-04-15 Hoffmann La Roche Tfn-bindende proteine
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5723286A (en) * 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ　アンティボディー　テクノロジー　リミティド 特異的な結合ペアーの構成員の製造方法
ATE224911T1 (de) 1990-07-17 2002-10-15 Univ Oklahoma Gmp-140 ligand
IE912365A1 (en) 1990-07-23 1992-01-29 Zeneca Ltd Continuous release pharmaceutical compositions
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
AU643141B2 (en) 1991-03-15 1993-11-04 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
WO1992016221A1 (en) 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US6139843A (en) 1991-04-02 2000-10-31 Albert Einstein College Of Medicine Of Yeshiva University Peptide compositions for the treatment of HIV
US5281698A (en) * 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) * 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5733731A (en) * 1991-10-16 1998-03-31 Affymax Technologies N.V. Peptide library and screening method
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
EP0897983B1 (en) * 1991-10-25 2003-05-07 Immunex Corporation Antibody against CD40-L
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
JPH07505915A (ja) 1992-04-14 1995-06-29 コーネル　リサーチ　ファウンデーション、インコーポレーテッド 樹枝状巨大分子およびその製造法
DK0615451T3 (da) 1992-05-26 2006-04-24 Immunex Corp Hidtil ukendt cytokin der binder til CD30
US5792451A (en) 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
EP0672068A4 (en) * 1992-09-25 1997-02-26 Commw Scient Ind Res Org TARGET MOLECULES BINDING POLYPEPTIDES.
GB9225448D0 (en) 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
NZ247231A (en) * 1993-03-23 1994-10-26 Holyoake Ind Ltd Diffuser for air conditioning system; outlet air direction thermostatically controlled
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
US5922545A (en) * 1993-10-29 1999-07-13 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5773569A (en) * 1993-11-19 1998-06-30 Affymax Technologies N.V. Compounds and peptides that bind to the erythropoietin receptor
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
GB2285446B (en) 1994-01-03 1999-07-28 Genentech Inc Thrombopoietin
US5608035A (en) * 1994-02-02 1997-03-04 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5786331A (en) * 1994-02-02 1998-07-28 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
US5880096A (en) * 1994-02-02 1999-03-09 Affymax Technologies N.V. Peptides and compounds that bind to the IL-1 receptor
WO1995021919A2 (en) 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
HUT75359A (en) 1994-02-14 1997-05-28 Univ Washington Hematopoietic protein and materials and methods for making it
BR9505781A (pt) * 1994-02-14 1996-03-05 Kirin Brewery Proteina tendo atividade TPO
US5795569A (en) * 1994-03-31 1998-08-18 Amgen Inc. Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
FI960136A7 (fi) 1994-03-31 1996-03-11 Amgen Inc Koostumuksia ja menetelmiä megakaryosyyttisen kasvun ja erikoistumisen stimuloimiseksi
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
IL116026A (en) * 1994-11-22 2005-08-31 Rhone Poulenc Rorer Sa Peptides capable of linking to the sh3 domain of gap, nucleotide sequences encoding the same, their preparation and uses
JP3511321B2 (ja) * 1994-11-29 2004-03-29 出光興産株式会社 スチレン系重合体の分子量制御方法
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
EP0796335A1 (en) 1994-12-07 1997-09-24 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
DE69534265T2 (de) 1994-12-12 2006-05-04 Beth Israel Deaconess Medical Center, Inc., Boston Chimäre zytokine und ihre verwendung
US5888763A (en) * 1994-12-30 1999-03-30 The Rockefeller University Peptides specific for the first Crk-SH3 domain
AU3204895A (en) 1995-02-01 1996-08-21 University Of Massachusetts Medical Center Methods of selecting a random peptide that binds to a target protein
IL113159A0 (en) 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6251864B1 (en) * 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
EA001220B1 (ru) * 1995-06-07 2000-12-25 Глаксо Груп Лимитед Пептид или пептидомиметик, который связывается с рецептором тромбоэтина, фармацевтическая композиция и способ лечения
YU34196A (sh) 1995-06-07 1999-03-04 Glaxo Group Limited Peptidi i jedinjenja koja se vezuju za receptor
US5767078A (en) 1995-06-07 1998-06-16 Johnson; Dana L. Agonist peptide dimers
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
IL118524A (en) 1995-06-19 2004-02-19 Akzo Nobel Nv Peptides and pharmaceutical preparations containing them useful in the treatment of peptide tolerance
PT2275119E (pt) 1995-07-27 2013-11-21 Genentech Inc Formulação de proteína liofilizada isotónica estável
US5746516A (en) * 1995-08-11 1998-05-05 Hitachi Powdered Metals Co., Ltd. Porous bearing system having internal grooves and electric motor provided with the same
WO1997008553A1 (en) 1995-08-22 1997-03-06 The Regents Of The University Of California Targeting of proteins to the cell wall of gram-positive bacteria
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
JPH09151200A (ja) 1995-09-29 1997-06-10 Ajinomoto Co Inc ヒト胃癌に対する免疫応答を誘導できるペプチド及び該ペプチドを含むヒト胃癌治療、予防剤
US5670110A (en) 1995-12-21 1997-09-23 The Procter & Gamble Company Method for making three-dimensional macroscopically-expanded webs having improved functional surfaces
US6369027B1 (en) 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
CN1154971A (zh) * 1996-01-19 1997-07-23 北京医科大学 血小板生长因子(tpo)及其制备方法和用途
US5714577A (en) * 1996-01-26 1998-02-03 University Of Pittsburgh Antimicrobial peptides
NZ503548A (en) 1996-02-09 2001-09-28 Amgen Inc A fusion protein comprising an IL-1ra receptor antagonist with a constant domain of human immunoglobulin at the carboxy terminus
IL117223A0 (en) 1996-02-22 1996-06-18 Yeda Res & Dev Antipathogenic polypeptides and compositions comprising them
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
AU2597897A (en) 1996-03-28 1997-10-17 Brigham And Women's Hospital Peptide ligands of the urokinase receptor
IL118003A0 (en) 1996-04-23 1996-08-04 Yeda Res & Dev Novel vip fragments and pharmaceutical compositions comprising them
FR2748028B1 (fr) 1996-04-30 1998-08-14 Lab Francais Du Fractionnement Peptides derives du facteur von willebrand et leur utilisation comme anticoagulant
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE69737229T2 (de) 1996-06-07 2008-01-31 Takeda Pharmaceutical Co. Ltd. Peptid mit cortistatin- oder somatostatin-aktivität, verfahren zu dessen herstellung und dessen verwendungen
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
JP2001501600A (ja) 1996-09-10 2001-02-06 ザ バーナム インスティテュート 腫瘍ホーミング分子、それに由来する結合体、およびその使用方法
US5932546A (en) 1996-10-04 1999-08-03 Glaxo Wellcome Inc. Peptides and compounds that bind to the thrombopoietin receptor
WO1998024477A1 (en) 1996-12-06 1998-06-11 Amgen Inc. Combination therapy using an il-1 inhibitor for treating il-1 mediated diseases
AU5606098A (en) 1996-12-20 1998-07-17 Amgen, Inc. Ob fusion protein compositions and methods
KR19980066046A (ko) 1997-01-18 1998-10-15 정용훈 고역가의 CTLA4-Ig 융합단백질
WO1998033812A1 (en) 1997-02-05 1998-08-06 Brigham And Women's Hospital, Inc. Mast cell protease peptide inhibitors
US5863735A (en) 1997-02-24 1999-01-26 Incyte Pharmaceuticals, Inc. Human transmembrane 4 superfamily protein
CZ302262B6 (cs) 1997-04-16 2011-01-19 Amgen Inc. Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
CN1202862C (zh) 1997-04-17 2005-05-25 安姆根有限公司 包含具有抗体Fc链的稳定、有活性人OB蛋白的结合物的组合物及方法
US6265535B1 (en) 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
WO1998055620A1 (en) 1997-06-06 1998-12-10 Regeneron Pharmaceuticals, Inc. Ntn-2 member of tnf ligand family
US6025140A (en) 1997-07-24 2000-02-15 Perseptive Biosystems, Inc. Membrane-permeable constructs for transport across a lipid membrane
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6238667B1 (en) 1997-09-19 2001-05-29 Heinz Kohler Method of affinity cross-linking biologically active immunogenic peptides to antibodies
EP1029034A4 (en) 1997-10-06 2003-04-09 Millennium Pharm Inc PROTEINS CONTAINING SIGNAL PEPTIDE AND THEIR USE
BR9814817A (pt) 1997-10-10 2002-01-08 Cytovia Inc Inibidores de apoptose de dipeptìdio e o uso dos mesmos
ES2173641T3 (es) 1997-11-07 2002-10-16 Conjuchem Inc Composicion de derivados opiaceos para la fabricacion de medicamentos.
AU2481399A (en) 1998-01-29 1999-08-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variant peptide ligands that selectively induce apoptosis
US6162613A (en) 1998-02-18 2000-12-19 Vertex Pharmaceuticals, Inc. Methods for designing inhibitors of serine/threonine-kinases and tyrosine kinases
WO1999045026A1 (en) * 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6235872B1 (en) 1998-03-12 2001-05-22 The Burnham Institute Proapoptotic peptides dependence polypeptides and methods of use
WO1999047151A1 (en) 1998-03-20 1999-09-23 Chugai Pharmaceutical Co., Ltd. Peptide ligands for the erythropoietin receptor
EP0947524A1 (en) 1998-03-30 1999-10-06 Upither B.V. Novel peptides for the treatment of autoimmune diseases
EP1075270B1 (en) 1998-04-06 2005-06-15 Advanced Immunit, Inc. Short peptide for treatment of neurological degenerative diseases
AU760381B2 (en) * 1998-04-28 2003-05-15 Laboratoires Serono Sa PEG-LHRH analog conjugates
EP0972780A1 (en) 1998-05-18 2000-01-19 Applied Research Systems ARS Holding N.V. Il-6 antagonist peptides
EP0958829B1 (en) 1998-05-21 2004-05-19 Tecnogen S.C.P.A. Use of a peptide compound in the treatment of systemic lupus erythematosus
BR9910639A (pt) 1998-05-22 2002-01-15 Abbott Lab Drogas anti-angiogênicas compreendendo peptìdeo
US5932548A (en) 1998-06-03 1999-08-03 Deghenghi; Romano Lysine containing peptides for treatment of heart disease
WO2000001402A1 (en) 1998-07-02 2000-01-13 Envision Biomedical Consulting Antiproliferative and antiviral proteins and peptides
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
AU770555B2 (en) 1998-08-17 2004-02-26 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
EP1105421A2 (en) 1998-08-21 2001-06-13 Yeda Research & Development Company, Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
PL219605B1 (pl) 1998-10-23 2015-06-30 Kirin Amgen Inc Dimeryczne mimetyki peptydów trombopoetynowych wiążące się z receptorem MP1 i wykazujące aktywność trombopoetyczną
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
WO2000047740A2 (en) 1999-02-12 2000-08-17 Amgen Inc. Tnf-related proteins
US6635646B1 (en) * 1999-05-04 2003-10-21 Schering Corporation Pegylated interferon alfa-CCR5 antagonist combination HIV therapy
EP1194451A1 (en) 1999-07-02 2002-04-10 Genentech, Inc. Fusion peptides comprising a peptide ligand domain and a multimerization domain
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
JP2003533187A (ja) 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
EP1589034B1 (en) 2000-12-05 2008-11-19 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
AU2002307062A1 (en) 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
US7332474B2 (en) 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
WO2004002417A2 (en) 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
KR20050033563A (ko) 2002-06-28 2005-04-12 센토코 인코포레이티드 포유동물 ｅｐｏ 모방 ｃｈ1 결실된 모방체, 조성물, 방법및 용도
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003291689A1 (en) 2002-10-31 2004-05-25 Protein Design Labs, Inc. Stable liquid pharmaceutical formulation of antibodies that are prone to isomerization
KR20160045936A (ko) 2002-12-20 2016-04-27 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
DK1675606T3 (en) 2003-08-28 2017-06-19 Janssen Pharmaceuticals Inc Peptides and compound that bind to thrombopoietin receptors
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
CA2600749C (en) 2005-03-10 2014-04-15 Nascacell Ip Gmbh Dimeric or multimeric microproteins
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007087428A2 (en) * 2006-01-25 2007-08-02 Amgen Inc. Thrombopoietic compounds
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
US8197642B2 (en) * 2007-07-26 2012-06-12 Nichiha Corporation Inorganic board and method for manufacturing the same
US10534898B2 (en) 2017-01-18 2020-01-14 International Business Machines Corporation Code identification

Also Published As

Publication number Publication date
SK287737B6 (sk) 2011-08-04
LTPA2009006I1 (lt) 2022-03-10
US20050080014A1 (en) 2005-04-14
CY1114940T1 (el) 2016-12-14
EA200100465A1 (ru) 2001-10-22
EP1783222A1 (en) 2007-05-09
IL142023A0 (en) 2002-03-10
FR09C0030I2 (fr) 2010-12-31
CY1107526T1 (el) 2010-07-28
DK1783222T3 (da) 2012-07-09
EP2319928B9 (en) 2014-04-16
JP4332163B2 (ja) 2009-09-16
US20090186822A1 (en) 2009-07-23
US9145450B2 (en) 2015-09-29
ES2388341T3 (es) 2012-10-11
DE69934425T2 (de) 2007-09-27
AR020934A1 (es) 2002-06-05
US9534032B2 (en) 2017-01-03
US20150024431A1 (en) 2015-01-22
LU91598I2 (fr) 2009-09-30
AU1223900A (en) 2000-05-15
EP2319928B1 (en) 2013-03-27
BG65663B1 (bg) 2009-05-29
ES2422231T3 (es) 2013-09-09
JP3820105B2 (ja) 2006-09-13
US20120208760A1 (en) 2012-08-16
US8748571B2 (en) 2014-06-10
HK1042114B (zh) 2006-09-29
TWI250988B (en) 2006-03-11
US6835809B1 (en) 2004-12-28
CA2346996C (en) 2013-11-19
SK4962001A3 (en) 2001-12-03
HUP0104327A3 (en) 2003-09-29
NO20011962L (no) 2001-06-21
RS51237B (sr) 2010-12-31
BG105401A (en) 2003-02-28
FR09C0030I1 (fr) 2009-09-25
CA2346996A1 (en) 2000-05-04
NL300398I1 (nl) 2009-10-01
PT1783222E (pt) 2012-07-26
CZ302155B6 (cs) 2010-11-18
US7994117B2 (en) 2011-08-09
JP2002536960A (ja) 2002-11-05
EP1124961A2 (en) 2001-08-22
WO2000024770A3 (en) 2000-09-14
EP1124961B9 (en) 2010-07-21
EP2319928A1 (en) 2011-05-11
DE69934425D1 (en) 2007-01-25
ME00238B (me) 2011-02-10
YU24301A (sh) 2005-07-19
US20120034657A1 (en) 2012-02-09
WO2000024770A9 (en) 2000-10-26
DK2319928T3 (da) 2013-06-24
NZ510529A (en) 2003-10-31
AU773891B2 (en) 2004-06-10
PL219605B1 (pl) 2015-06-30
KR20010099695A (ko) 2001-11-09
JP2006230413A (ja) 2006-09-07
LU91598I9 (OSRAM) 2019-01-03
CN1810832A (zh) 2006-08-02
LTC1124961I2 (lt) 2022-03-25
HUP0104327A2 (hu) 2002-02-28
HK1093075A1 (en) 2007-02-23
BR9914698B1 (pt) 2014-04-29
BRPI9914698B8 (pt) 2021-05-25
KR100719202B1 (ko) 2007-05-16
MEP42108A (en) 2011-02-10
CN1325447A (zh) 2001-12-05
PL348041A1 (en) 2002-05-06
ES2279649T3 (es) 2007-08-16
EA003998B1 (ru) 2003-12-25
SI1124961T1 (sl) 2007-06-30
NO20011962D0 (no) 2001-04-20
CZ20011287A3 (cs) 2001-10-17
DK1124961T3 (da) 2007-04-10
HK1042114A1 (en) 2002-08-02
CY2009012I1 (el) 2010-07-28
MY126795A (en) 2006-10-31
TWI257394B (en) 2006-07-01
NO331027B1 (no) 2011-09-12
CN1250721C (zh) 2006-04-12
EP1124961B1 (en) 2006-12-13
SI1783222T1 (en) 2012-09-28
ATE348163T1 (de) 2007-01-15
NO2012005I2 (no) 2015-02-02
PT2319928E (pt) 2013-06-28
SI2319928T1 (sl) 2013-08-30
DE122009000039I1 (de) 2009-11-05
CY2009012I2 (el) 2010-07-28
ZA200102102B (en) 2001-11-15
EP1783222B1 (en) 2012-06-06
PT1124961E (pt) 2007-02-28
US20070142295A1 (en) 2007-06-21
US20060189531A1 (en) 2006-08-24
US8618044B2 (en) 2013-12-31
WO2000024770A2 (en) 2000-05-04
CN1810832B (zh) 2012-12-12
BG110221A (en) 2009-06-30
NL300398I2 (nl) 2009-12-01
BG66190B1 (bg) 2011-12-30
CY1113107T1 (el) 2016-04-13
BR9914698A (pt) 2003-01-07
TW200606175A (en) 2006-02-16
US8044174B2 (en) 2011-10-25
NO2012005I1 (no) 2012-04-02
HU228582B1 (en) 2013-04-29

Similar Documents

Publication Publication Date Title
AU773891C (en) Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity
EP1439852B1 (en) Peptides and related compounds having thrombopoietic activity
US20110071077A1 (en) Thrombopoietic Compounds
HK1157817A (en) Dimeric thrombopoietin peptide mimetics binding to mp1 receptor and having thrombopoietic activity
AU2002340176A1 (en) Peptides and related compounds having thrombopoietic activity
AU2007201923A1 (en) Peptides and related compounds having thrombopoietic activity

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20040909